On July 30, 2025 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, reported that it has signed a non-binding term sheet with Evotec SE (Press release, Sandoz, JUL 30, 2025, View Source [SID1234654611]). This paves the way for Sandoz to potentially acquire 100% of the issued and outstanding equity interests of Just–Evotec Biologics EU SAS for an amount of around USD 300 million, which owns the J.POD biologics development and manufacturing facility in Toulouse, France.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Richard Saynor, CEO of Sandoz, said: "We aim to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The intended acquisition is fully in line with our strategy to reinforce in-house biosimilar capabilities, while creating additional strategic flexibility. Following successful completion, the Toulouse site would be used to develop and manufacture Sandoz biosimilars. JEB´s fully automated and high throughput technology platform will help us move faster, scale smarter, and maintain high quality while keeping costs under control."

Sandoz and Evotec SE will now work to negotiate details of the contracts and carry out the relevant works-council consultation processes, as well as the mandatory employee bid process in France. Closing the proposed transaction will be subject to finalizing the contracts and obtaining all necessary approvals. Further details of the terms cannot be shared at this stage and will only be disclosed after successful signing of the contracts.

Just-Evotec Biologics has been a key strategic partner for Sandoz since 2023. The proposed acquisition would complement previously announced investments in Sandoz biosimilar manufacturing and development sites. The planned investment would be in line with existing Sandoz capital-expenditure commitments related to Sandoz operations in Europe.

Upon completion of the proposed transaction, JEB employees would transfer with the acquired entity and would become part of the Sandoz Group. JEB brings an advanced and integrated continuous manufacturing platform with automation that enables manufacturing to run continuously end-to-end.

On July 29, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (" BriaCell "), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (" BriaPro "), reported that BriaPro is developing novel multivalent agents for cancer treatment (Press release, BriaCell Therapeutics, JUL 29, 2025, View Source [SID1234655035]). BriaPro has filed a provisional patent application for the underlying platform referred to as "TILsRx".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The TILsRx platform enables simultaneous engagement of multiple tumor-associated and immune pathway targets. Multivalent agents (including antibodies, soluble receptors and cytokines) address immune suppression and T cell exhaustion often seen with tumor-infiltrating lymphocytes (TILs) and aim to improve T cell activation and persistence in the tumor microenvironment. Designed to activate TILs and enhance TIL binding to tumor cells as well as block immune checkpoints that suppress anti-tumor responses, TILsRx agents are multifunctional in their cancer killing actions. Specific elements in TILsRx agents include soluble CD80, which has a dual function as an immune checkpoint inhibitor and as an immunostimulator, anti-CD3, which is a potent T cell activator, IL-21, which is an enhancer of cytotoxic T cell function, and anti-STEAP1 (STEAP1 is a cancer antigen expressed in prostate cancer among others). An early candidate target is B7-H3, a tumor antigen which is overexpressed in prostate, lung, breast, pancreatic, and ovarian cancer while minimally expressed in normal tissue.

"We have developed novel multivalent anti-cancer agents which we expect to be both highly selective and highly effective, maximizing on-target efficacy while minimizing off-target toxicity to provide improved clinical responses in multiple indications," stated Miguel Lopez-Lago, PhD, BriaCell and BriaPro CSO.

"The TILsRx platform reflects our goal to develop an effective and safe class of therapeutics for cancer patients. TILsRx agents combine shared core components that improve manufacturing efficiency with elements that target specific cell surface antigens. This strategy provides the flexibility to include new immunotherapy targets identified in the future. We look forward to advancing this exciting technology through pre-clinical and clinical stages," stated Markus D. Lacher, PhD, a key inventor of the technology.

"Our advanced multivalent technology provides us with a platform to quickly expand our proprietary pipeline of novel immuno-oncology programs in BriaPro in a cost-effective manner," stated Dr. William V. Williams, BriaPro and BriaCell President & CEO. "We anticipate that the multivalent approach will have activity against multiple types of cancers and may also synergize with BriaCell’s cell-based cancer vaccine programs."

On July 29, 2025 Merck & Co reported financial results for second quarter 2025 (Presentation, Merck & Co, JUL 29, 2025, View Source [SID1234654714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 29, 2025 AstraZeneca reported the first half and second quarter 2025 financial results (Press release, AstraZeneca, JUL 29, 2025, View Source [SID1234654662]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 29, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world (Press release, Guardant Health, JUL 29, 2025, View Source [SID1234654621]). The data, published today in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), found that Guardant Reveal successfully detected responses to immunotherapy across multiple solid tumor types in advanced stage cancer patients and identified non-responders more than three months—and in some cases nearly five months—before disease progression was visible by standard methods.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approximately 30% of patients with advanced-stage cancer receive immunotherapy treatment, with varying degree and duration of response. This study analyzed a large cohort of more than 500 patients with various advanced solid tumors, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers, receiving immunotherapy in a real-world setting to assess if blood-based monitoring could predict response accurately and faster than standard of care methods. The strong association found between long-term patient outcomes and changes in tumor fraction as measured with the tissue-free, methylation-based Guardant Reveal supports the use of blood-based monitoring to help predict treatment response and improve decision-making in cancer care.

"Precise serial monitoring at the molecular level provides real value to oncologists and to patients using immunotherapy," said Craig Eagle, M.D., Chief Medical Officer at Guardant Health. "This study shows that Guardant Reveal has the potential to revolutionize how oncologists assess patient response, identifying earlier insights that can empower them to make informed decisions faster and improve patient outcome and quality of care."

"Our RADIOHEAD study of Guardant Reveal in advanced stage cancers provides patients with a new caliber of precision monitoring in order to create better patient outcomes," said Tarak Mody, PhD, Chief Business Officer at PICI. "These findings exemplify PICI’s commitment to forging mission-driven partnerships to bring cutting-edge technology into clinical practice, accelerate discoveries, and advance the development of curative immune therapies for patients."

Key study findings include:

Improved patient outcomes associated with any reduction in tumor fraction
75% lower risk of progression in patients with ≥80% decrease in tumor fraction
Disease progression identified up to 5 months prior to standard of care methods